Brief: Neuren Pharmaceuticals Provides Half-Year Shareholder Update-
24/08/2022 02:33
Aug 24 (Reuters) - Neuren Pharmaceuticals NEU.AX :
* HALF-YEAR SHAREHOLDER UPDATE-NEU.AX
* SUBJECT TO APPROVAL OF NDA FOR TROFINETIDE, SEES REVENUE
OVER
2022 AND 2023 FOR RETT SYNDROME IN US ALONE OF A$118 MILLION
Source text for Eikon: ID:nASX2fK777
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union